Company Overview & Vision - Aliv is building consumer software products aiming to improve users' lives [3] - The company's vision is to create a portfolio of "one person billion-dollar companies" [34] - Aliv emphasizes a lean startup approach, focusing on small teams and early profitability [1][2] Key Achievements & Metrics - Aliv scaled a portfolio of products to $6 million in ARR (Annual Recurring Revenue) profitably [3] - The company has generated over 500 million views across social media [3] - One product, Unstuck AI, reached 1 million users in under nine weeks [8] - Another product launch saw 10,000 users in less than 30 hours [4] Lean Operating Principles - Prioritizes hiring "10xer generalists" with complementary skills [10][11] - Emphasizes a "profit-first mentality" to guide decision-making [11][12] - Focuses on continuous process refinement and learning from failures [13] - Leverages "super tools" by reinventing the ways to use old tools and consolidating workflows [14][15] - Believes in building compounding benefits through technical playbooks and operational blueprints [14][15] Organizational Structure - Adopts a "harvester and cultivator" model for its engineering organization, inspired by Palantir [21][22] - Harvesters are product engineers who own and manage their products end-to-end [22][23] - Cultivators are AI software engineers focused on building the company's agentic operating system and automation [24] AI Tooling & Automation - Uses AI tooling to augment existing talent, not to compensate for shortcomings [25] - Implements a three-stage automation strategy: human-led tooling, workflow automation, and autonomous decision-making systems [28][29][30] - Aims to build a company where strategic insights are provided by people, but operations are run by AI agents [30] - Explores using AI agents for market research, acquisition target scoring, and growth system automation [30][31]

"If you want to go viral, you’re testing a format on the whole world."Devon Rodriguez, a social media content creator on the #ForbesTopCreators list, shared with Forbes his journey as an artist and advice on going viral.Get the full list: https://t.co/QdpaO5Foso https://t.co/vPX70IfLU6 ...

Core Insights - Traws Pharma is advancing its antiviral pipeline with multiple regulatory submissions for tivoxavir marboxil (TXM) and ratutrelvir, targeting seasonal and bird flu as well as COVID-19 [1][2][3] Group 1: Tivoxavir Marboxil (TXM) - A Phase 2 study protocol has been submitted to evaluate TXM in patients with seasonal influenza and H5N1 bird flu, aiming for a non-inferiority comparison with XOFLUZA® [2][3] - The study will enroll subjects in Australia and Southeast Asia, regions with high rates of human bird flu infections, to assess TXM's efficacy [2][3] - Traws Pharma is in discussions with the FDA regarding accelerated approval pathways for TXM under the Animal Rule [4][3] - TXM is designed as a single-dose oral treatment with demonstrated in vitro activity against various influenza strains, including H5N1 [8] Group 2: Ratutrelvir - A separate Phase 2 study protocol has been submitted for ratutrelvir, a protease inhibitor for newly diagnosed COVID patients, comparing it to PAXLOVID [4][6] - The study will evaluate a 10-day treatment regimen for ratutrelvir against the 5-day regimen for PAXLOVID, focusing on efficacy, safety, disease rebound, and Long COVID incidence [4][5] - Ratutrelvir is positioned as a ritonavir-independent treatment, potentially broadening its use among patients ineligible for PAXLOVID [9][6] Group 3: Market Potential - The seasonal influenza antiviral market represents a multi-billion dollar opportunity, driven by global health organizations and potential pandemic outbreaks [8] - The COVID-19 treatment market also presents significant potential, with ratutrelvir aiming to address gaps in existing therapies [9]

Devon Rodriguez, a social media content creator on the #ForbesTopCreators list, shared with Forbes his journey as an artist and advice on going viral. https://t.co/ZtBgNGlg82 https://t.co/dVG6e2Yg3N ...

#ForbesTopCreators: Alongside a bold new wave of digital comics, Adam Waheed is going viral—and rewriting the rules of showbiz. (Photo: Cody Pickens for Forbes) https://t.co/3BVlil9z1p https://t.co/pi7XuAsbeL ...

Core Insights - IMUNON, Inc. announced positive results from a Phase 1 clinical trial of its investigational DNA plasmid vaccine, IMNN-101, which demonstrated better durability of protection compared to mRNA vaccines after a single dose targeting the SARS-CoV-2 Omicron XBB1.5 variant [3][4] - The company is seeking strategic partnerships to advance its PlaCCine technology platform and fund its core pipeline with non-dilutive capital [1][4] Company Overview - IMUNON is a clinical-stage biotechnology company focused on developing non-viral DNA-mediated immunotherapies and next-generation vaccines [1][8] - The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer, which has completed multiple clinical trials [9] Clinical Trial Details - The Phase 1 trial enrolled 24 participants and evaluated three escalating doses of IMNN-101, with a focus on safety, tolerability, and immunogenicity [6] - Results indicated a median increase of up to 3-fold in serum neutralizing antibody titers at six months, with no serious adverse effects reported [3][6] Technology Advantages - The PlaCCine technology platform offers several competitive advantages, including better durability of protection, temperature stability, and ease of manufacturing compared to current mRNA vaccines [4][5] - IMNN-101 utilizes a proprietary DNA plasmid that regulates the expression of key pathogen antigens, providing flexibility in manufacturing and delivery [5]

Expensify (EXFY) 2025 Conference June 10, 2025 01:00 PM ET Speaker0 Alright. Well, good afternoon and good morning, everybody. Dan Jester, BMO Software Research here. Thanks again for joining our next session of our virtual event today. We're very pleased to have Expensify joining us, and we have Derek David Barrett, is the founder and the CEO with us today. So, David, thanks for joining us. Speaker1 Hey. Thanks so much for having me. Speaker0 Pleasure. Thank you so much. In terms of logistics, for those of ...

Corporate Presentation June 5, 2025 Forward Looking Statements Disclaimer This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research and development programs, our business and the industry in which we operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward ...

Core Viewpoint - Cocrystal Pharma, Inc. is presenting its broad-spectrum protease inhibitor CDI-988 at the 2025 Military Health System Research Symposium, highlighting its potential as a prophylaxis and treatment for norovirus, which currently lacks approved antiviral agents or vaccines [1][2]. Company Overview - Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics targeting the replication processes of various viruses, including noroviruses, coronaviruses, and hepatitis C viruses [6]. - The company utilizes unique structure-based technologies and expertise in enzymology and medicinal chemistry to create first- and best-in-class antiviral drugs [6]. Product Development - CDI-988 is designed as a broad-spectrum inhibitor targeting a highly conserved region in the active site of 3CL viral proteases, representing a first-in-class oral treatment for noroviruses and coronaviruses [3]. - The company has completed a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of CDI-988 in healthy adults, which included a food effect cohort [3]. Technology Platform - Cocrystal's proprietary structure-based platform technology provides a three-dimensional structure of inhibitor complexes at near-atomic resolution, facilitating the identification of novel binding sites and rapid structural information processing [4]. - The goal of this technology is to develop antiviral therapies that are safe, well-tolerated, and effective against all viral subtypes, with a high barrier to viral resistance [4]. Industry Context - The Military Health System Research Symposium is an annual event that gathers military medical care providers, researchers, and industry representatives to discuss healthcare initiatives related to military infectious diseases and operational medicine [5].

enGene Holdings (ENGN) 2025 Conference June 04, 2025 11:05 AM ET Speaker0 Well, thank you very much. It's a delight to be here, and I'm grateful for this opportunity to speak about NGIN, which is a non viral genetic medicines company that's at a very important stage in our life cycle. I'm looking forward to sharing more about that with all of you. So again, thank you to the conference organizers for this opportunity. As you will expect, I'm gonna be making some forward looking statements during today's pres ...